Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 5/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132840 | 0.93 | F2 (0.73) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL7134194 | 0.91 | CTSL (0.58) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL14684392 | 0.91 | HDAC8 (0.64) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL7317573 | 0.91 | HDAC8 (0.64) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL4321567 | 0.91 | TACR1 (0.67) | CTSLCTSSCTSKCTSBTACR1 | |
| SCHEMBL7038484 | 0.88 | HDAC8 (0.78) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL10706786 | 0.87 | HDAC8 (0.68) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL7326086 | 0.87 | HDAC8 (0.60) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL7269586 | 0.86 | HDAC8 (0.59) | HDAC8F2CTSLCTSSCTSK | |
| SCHEMBL4154649 | 0.86 | HDAC8 (0.80) | HDAC8F2CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | HDAC8 825/4885F2 731/4885CTSL 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.